A group from GLYcoDiag, 2 Rue du Cristal, Orléans, France, etc. has reported about lectin analysis of SARS-CoV-2-positive nasopharyngeal samples.
I have decided to stop blogging about SARS-CoV-2 related issues, but oh well!
GlycoDIAG’s GLYcoPROFILE® technology clearly indicated the glycan differences between SARS-CoV-2-positive and -negative samples.
BPA and PHA-E were able to discriminate the control group from SARS-CoV-2-positive samples, with values around or higher than 3000. The BPA recognizes GalNAc-containing glycans, while PHA-E binds to bi-antennary complex N-glycans. In addition, another group of lectins, including WFA (binds to LacdiNAc), GSL-II (binds to agalacto) and PHA-L (binds to tri/tetra antennary complex N-glycan), were also distinguishing for SARS-CoV-2-positive samples. The HHA lectin was confirmed as a negative reference lectin.